Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-26-170314
Filing Date
2026-04-22
Accepted
2026-04-22 16:01:53
Documents
16
Period of Report
2026-04-22

Document Format Files

Seq Description Document Type Size
1 DEF 14A antx-20260422.htm   iXBRL DEF 14A 1067869
2 GRAPHIC img183921429_0.gif GRAPHIC 6885
3 GRAPHIC img183921429_1.jpg GRAPHIC 11099
4 GRAPHIC img183921429_2.jpg GRAPHIC 11099
5 GRAPHIC img183921429_3.jpg GRAPHIC 78454
6 GRAPHIC img183921429_4.jpg GRAPHIC 116556
  Complete submission text file 0001193125-26-170314.txt   1876391

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20260422.xsd EX-101.SCH 7582
19 EXTRACTED XBRL INSTANCE DOCUMENT antx-20260422_htm.xml XML 6031
Mailing Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025
Business Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41331 | Film No.: 26883643
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)